Sequential Combination of Electro-Fenton and Electrochemical Chlorination Processes for the Treatment of Anaerobically-Digested Food Wastewater

2017 ◽  
Vol 51 (18) ◽  
pp. 10700-10710 ◽  
Author(s):  
Yong-Uk Shin ◽  
Ha-Young Yoo ◽  
Seonghun Kim ◽  
Kyung-Mi Chung ◽  
Yong-Gyun Park ◽  
...  
Author(s):  
Hiromitsu Noguchi ◽  
Masahide Kubo ◽  
Kayo Kashiwada‐Nakamura ◽  
Katsunari Makino ◽  
Jun Aoi ◽  
...  

2021 ◽  
Vol 6 (1) ◽  
pp. e000688
Author(s):  
Focke Ziemssen ◽  
You-Shan Feng ◽  
Sven Schnichels ◽  
Tarek Bayyoud ◽  
Marius Ueffing ◽  
...  

IntroductionThe actual prevalence of a SARS-CoV-2 infection and the individual assessment of being or having been infected may differ. Facing the great uncertainty—especially at the beginning of the pandemic—and the possibility of asymptomatic or mildly symptomatic, subclinical infections, we evaluate the experience of SARS-CoV-2 antibody screening at a tertiary clinical setting.Methods and analysisAll employees of a tertiary eye centre and a research institute of ophthalmology were offered antibody testing in May 2020, using a sequential combination of different validated assays/antigens and point-of-care (POC) testing for a subset (NCT04446338). Before taking blood, a systematic inquiry into past symptoms, known contacts and a subjective self-assessment was documented. The correlations between serostatus, patient contacts and demographic characteristics were analysed. Different tests were compared by Kappa statistics.ResultsAmong 318 participants, SARS-CoV-2 antibodies were detected in 9 employees. Chemiluminescence assays (chemiluminescence immunoassay and electrochemiluminescence) showed superior specificity and high reproducibility, compared with ELISA and POC results.In contrast to the low seropositivity (2.8%) of healthcare workers, higher than that of the other departments of the hospital, a large proportion mistakenly assumed that they might have already been infected. Antiviral antibody titres increased and remained on a plateau for at least 3 months.ConclusionsThe great demand and acceptance confirmed the benefit of highly sensitive testing methods in the early phase of the pandemic. The coincidence of low seroprevalence and anxious employees may have contributed to internalising the need of hygiene measures.


2013 ◽  
Vol 31 (35) ◽  
pp. 4424-4430 ◽  
Author(s):  
Sergio Amadori ◽  
Stefan Suciu ◽  
Roberto Stasi ◽  
Helmut R. Salih ◽  
Dominik Selleslag ◽  
...  

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients and Methods Patients (n = 472) age 61 to 75 years were randomly assigned to induction chemotherapy with mitoxantrone, cytarabine, and etoposide preceded, or not, by a course of GO (6 mg/m2 on days 1 and 15). In remission, patients received two consolidation courses with or without GO (3 mg/m2 on day 0). The primary end point was overall survival (OS). Results The overall response rate was comparable between the two arms (GO, 45%; no GO, 49%), but induction and 60-day mortality rates were higher in the GO arm (17% v 12% and 22% v 18%, respectively). With median follow-up of 5.2 years, median OS was 7.1 months in the GO arm and 10 months in the no-GO arm (hazard ratio, 1.20; 95% CI, 0.99 to 1.45; P = .07). Other survival end points were similar in both arms. Grade 3 to 4 hematologic and liver toxicities were greater in the GO arm. Treatment with GO provided no benefit in any prognostic subgroup, with the possible exception of patients age < 70 years with secondary AML, but outcomes were significantly worse in the oldest age subgroup because of a higher risk of early mortality. Conclusion As used in this trial, the sequential combination of GO and standard chemotherapy provides no benefit for older patients with AML and is too toxic for those age ≥ 70 years.


2018 ◽  
Vol 36 (4) ◽  
pp. 119-125
Author(s):  
Jana C. Lee ◽  
Barry Finley ◽  
S. Michael Flores ◽  
Katerina Velasco Graham ◽  
J. Megan Woltz ◽  
...  

Abstract The azalea lace bug, Stephanitis pyrioides, is a serious pest of azaleas and rhododendrons which is often controlled by systemic insecticides. However, the efficacy of softer approaches such as biological control and water sprays against this pest on rhododendrons is unknown. Therefore, we tested the commercially available green lacewing predator, Chrysoperla rufilabris, and water sprays on lace bug infestation in one laboratory and four field trials. First, 2nd instar predator larvae were confirmed to consume lace bug nymphs and sometimes adults. Second, tapping predator larvae from hexcel units over dry leaves of potted rhododendrons and shaking loose eggs over wet leaves were reliable application methods. Third, predator larvae released onto potted rhododendrons lowered lace bug counts for two weeks. Fourth, after four bi-weekly applications, plants receiving egg cards or water-sprays had reduced lace bug counts and fewer damaged leaves than control plants. Fifth, landscape plants receiving the sequential combination of water spray followed by predator egg releases had 44 to 90% lower lace bug abundance and fewer damaged leaves than the control. After lace bugs were initially dislodged, hatching predators might have consumed hatching lace bugs. Index words: biological control, Chrysoperla rufilabris (Burmeister), mechanical control, rhododendron, Stephanitis pyrioides (Scott) Species used in this study: Azalea lace bug (Stephanitis pyrioides Scott), green lacewing (Chrysoperla rufilabris Burmeister), Rhododendron (Rhododendron spp.)


Sign in / Sign up

Export Citation Format

Share Document